Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : TD Cowen
Deal Size : $40.0 million
Deal Type : Public Offering
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
Details : The company intends to use the net proceeds from this offering to fund clinical development of PCM-075 (onvansertib) for the first-line RAS-mutated metastatic colorectal cancer.
Product Name : PCM-075
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 10, 2024
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : TD Cowen
Deal Size : $40.0 million
Deal Type : Public Offering
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cardiff Oncology Announces Positive Initial Data from RAS-mutated mCRC Clinical Trial
Details : PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.
Product Name : PCM-075
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cardiff Doses First Patient in First-Line RAS-Mutated Metastatic Colorectal Cancer Trial
Details : PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.
Product Name : PCM-075
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cardiff Provides Update on Phase 2 ONSEMBLE Trial in Patients with RAS-Mutated mCRC
Details : PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.
Product Name : PCM-075
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma.
Product Name : PCM-075
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 08, 2023
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onvansertib,Irinotecan HCl Trihydrate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PCM-075 (onvansertib) is a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated cancers.
Product Name : PCM-075
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2023
Lead Product(s) : Onvansertib,Irinotecan HCl Trihydrate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, reported in Phase 1b/2 clinical trial of PCM-075 (onvansertib) plus FOLFIRI/bevacizumab in second-line KRAS-mutated mCRC.
Product Name : PCM-075
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2022
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onvansertib,Olaparib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data showed that combining PCM-075 (onvansertib) with olaparib led to a statistically significant survival benefit compared to treatment with either agent alone in each of the three evaluated PDX models. Results showed combination was well tolerated.
Product Name : PCM-075
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : Onvansertib,Olaparib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022
Details : PCM-075 (onvansertib) effectively targets PLK1 an enzyme over-expressed in many cancer types. It’s been known for decades to to be hijacked by tumor cells allowing uncontrolled growth in the M phase of the cell cycle.
Product Name : PCM-075
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 09, 2022
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 1b/2 trial of onvansertib in combination with standard-of-care FOLFIRI and Avastin® (bevacizumab) to evaluate the safety and preliminary efficacy of the combination regimen in the second-line treatment of patients with KRAS-mutated mCRC.
Product Name : PCM-075
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2022
Lead Product(s) : Onvansertib,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable